Exhibits acetylcholine binding activity; acetylcholine receptor activity; and acetylcholine-gated cation-selective channel activity. Predicted to contribute to extracellular ligand-gated ion channel activity. Involved in several processes, including acetylcholine receptor signaling pathway; regulation of synaptic vesicle exocytosis; and response to nicotine. Localizes to several cellular components, including the cholinergic synapse; dopaminergic synapse; and integral component of plasma membrane. Used to study visual epilepsy. Human ortholog(s) of this gene implicated in lung cancer. Orthologous to human CHRNA3 (cholinergic receptor nicotinic alpha 3 subunit); PARTICIPATES IN acetylcholine signaling pathway via nicotinic acetylcholine receptor; nicotine pharmacodynamics pathway; nicotine pharmacokinetics pathway; INTERACTS WITH (S)-anabasine; (S)-nicotine; 3H-1,2-dithiole-3-thione.
Ethinyl Estradiol inhibits the reaction [Acetylcholine affects the activity of [CHRNA3 protein binds to CHRNB4 protein]], Ethinyl Estradiol inhibits the reaction [Tamoxifen inhibits the reaction [Acetylcholine affects the activity of [CHRNA3 protein binds to CHRNB4 protein]]]
Estradiol inhibits the reaction [Acetylcholine affects the activity of [CHRNA3 protein binds to CHRNB4 protein]], Estradiol promotes the reaction [Tamoxifen inhibits the reaction [Acetylcholine affects the activity of [CHRNA3 protein binds to CHRNB4 protein]]]
4-nonylphenol inhibits the reaction [Acetylcholine affects the activity of [CHRNA3 protein binds to CHRNB4 protein]], 4-nonylphenol promotes the reaction [Tamoxifen inhibits the reaction [Acetylcholine affects the activity of [CHRNA3 protein binds to CHRNB4 protein]]]
Atracurium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]], Atracurium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]]
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRNA3 mRNA
bisphenol A inhibits the reaction [Acetylcholine affects the activity of [CHRNA3 protein binds to CHRNB4 protein]], bisphenol A promotes the reaction [Tamoxifen inhibits the reaction [Acetylcholine affects the activity of [CHRNA3 protein binds to CHRNB4 protein]]]
Carbaryl results in decreased activity of [CHRNA3 protein binds to CHRNB2 protein], Carbaryl results in decreased activity of [CHRNA3 protein binds to CHRNB4 protein]
cisatracurium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]], cisatracurium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]]
Diethylstilbestrol inhibits the reaction [Acetylcholine affects the activity of [CHRNA3 protein binds to CHRNB4 protein]], Diethylstilbestrol promotes the reaction [Tamoxifen inhibits the reaction [Acetylcholine affects the activity of [CHRNA3 protein binds to CHRNB4 protein]]]
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRNA3 mRNA
EPTC results in decreased activity of [CHRNA3 protein binds to CHRNB2 protein], EPTC results in decreased activity of [CHRNA3 protein binds to CHRNB4 protein]
fenoxycarb results in decreased activity of [CHRNA3 protein binds to CHRNB2 protein], fenoxycarb results in decreased activity of [CHRNA3 protein binds to CHRNB4 protein]
mivacurium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]], mivacurium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]]
Pancuronium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]], Pancuronium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]]
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRNA3 mRNA
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CHRNA3 mRNA
rocuronium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]], rocuronium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]]
4-nonylphenol promotes the reaction [Tamoxifen inhibits the reaction [Acetylcholine affects the activity of [CHRNA3 protein binds to CHRNB4 protein]]] more ...
Tubocurarine inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]], Tubocurarine inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]]
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRNA3 mRNA
Varenicline binds to and results in increased activity of [CHRNA3 protein binds to CHRNB2 protein], Varenicline binds to and results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]
Vecuronium Bromide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]], Vecuronium Bromide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]]
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Gene-Chemical Interaction Annotations
